A ‘Wait-and-See’ Vibe Dominates Biotech’s Biggest Event of the Year
Executives attending J.P. Morgan conference don’t expect to find easy money in 2025 By Rowan Walrath C&EN Cartography Biosciences CEO Kevin Parker doesn’t see 2025 being much better than 2024 when it comes to financing opportunities for biotechnology companies...
Halia Therapeutics to Attend the 43rd J.P. Morgan Healthcare Conference and Present at BioPharma Obesity Innovation Forum in San Francisco
LEHI, Utah, Jan. 8, 2025 /PRNewswire/ -- Halia Therapeutics, a biopharmaceutical company at the forefront of developing treatments for chronic inflammation and related disorders, announced today that its leadership team will attend and participate in a panel...
Targeted Oncology – HT-6184 Advances to Second Stage of Phase 2 Trial in LR-MDS
Positive topline data from a phase 2 trial show HT-6184, an allosteric NEK7/NLRP3 inflammasome inhibitor, improves hematologic response in lower-risk MDS. Jordyn Sava December 17, 2024 The second stage of a phase 2 trial exploring the first-in-class allosteric...
Citeline-In Vivo – The Future Of Inflammation: The Inflammasome And BeyondCiteline – In Vivo:
David Wild interviews David Bearss, CEO of Halia Therapeutics Read the article here
Halia Therapeutics to Present Promising Data at Obesity Week 2024
HT-6184 Shows Enhanced and Sustained Weight Loss with GLP-1 Agonist Combination for Obesity LEHI, Utah, October 31, 2024 /PRNewswire/—Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company pioneering innovative treatments for chronic...
BIO News – BIF 2024: What’s happening with neurodegenerative disease targets and pipelines?
BIO News BIF 2024: What’s happening with neurodegenerative disease targets and pipelines? https://bio.news/bio-convention/neurodegenerative-disease-targets-and-pipelines-bif-2024-bio-investor-forum/ Clary Estes October 15, 2024 There is a great degree of renewed...
Halia Therapeutics to Participate in Panel at BIO Investor Forum 2024
Dr. David J. Bearss, CEO, will partake in a panel focused on Neurodegenerative Disease Targets and Pipelines on Tuesday, October 15 at 11:00-11:50 am PT LEHI, Utah, Oct. 14, 2024 /PRNewswire/ -- Halia Therapeutics, Inc. (Halia), a clinical-stage...
Biotech 2050 – Dr. David Bearss, Co-Founder & CEO of Halia, on Pioneering Genetic Discoveries to Defeat Alzheimer’s
Listen to Dr David Bearss discuss Halia's work on Alzheimer's and other inflammation-related diseases https://podcasts.apple.com/us/podcast/dr-dave-bearss-co-founder-ceo-of-halia-on-pioneering/id1482108463?i=1000671780322 Explore the forefront of biotech innovation as...
Dr David Bearss Discusses FDA and Safer Cancer Drugs
For decades drugmakers have taken a more-is-more model when dosing cancer drugs in clinical trials. U.S. regulators want them to reconsider that approach. Companies with cancer drugs in clinical trials must strike a balance between doses high enough to thwart...